MP35-07 COMPARISON OF THREE DIFFERENT TADALAFIL REGIMES FOR THE TREATMENT OF ERECTILE DYSFUNCTION IN DIABETES MELLITUS PATIENTS WITH MICROVASCULAR COMPLICATIONS

Abstract

You have accessJournal of UrologyCME1 May 2022MP35-07 COMPARISON OF THREE DIFFERENT TADALAFIL REGIMES FOR THE TREATMENT OF ERECTILE DYSFUNCTION IN DIABETES MELLITUS PATIENTS WITH MICROVASCULAR COMPLICATIONS Goksel Bayar, and Caglar Yildirim Goksel BayarGoksel Bayar More articles by this author , and Caglar YildirimCaglar Yildirim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002589.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We aimed to compare the efficacy and safety of daily, on-demand and daily plus optional tadalafil use in patients with microvascular complications due to diabetes mellitus (DM) and erectile dysfunction (ED). METHODS: Patients who came to our urology outpatient clinic with ED between May 2018 and March 2020, those with at least one microvascular complication due to DM (retinopathy, nephropathy, neuropathy or diabetic foot without macrovascular complications) were selected. Those with an international erectile function index score (IIEF-5) below 11 (severe and moderate) were included in the study. The patients were divided into three groups; the first group 5 mg tadalafil (Cialis™, Lilly, USA) daily, the second group 20 mg tadalafil (Cialis™, Lilly, USA) twice a week two hours before intercourse, and the third group 5 mg tadalafil daily and 2 hours before intercourse twice a week was formed to take an extra 15 mg (20 mg total on the intercourse day) tadalafil. The IIEF-5 form filled with at the first admission. The IIEF-5, SEP-2, SEP-3, GAQ-1 and GAQ-2 inquiry forms were filled 3 months after the treatment. RESULTS: A total of 60 patients, 20 in each group, were included in the study. The mean age, body mass index and baseline IIEF-5 scores of the patients were similar. In the post-treatment IIEF-5 scores, the third group (13+4.7) was significantly higher than the first (8.35+2.6) (p=0.001) and the second group (10+3.6) (p=0.035); there was no significant difference between the first and second groups (p=0.345). Although the percentage of positive answers to SEP-2 and GAQ-1 questions was different between the groups, this difference was not statistically significant. However, the percentage of patients who answered positively to the questions SEP-3 (20%, 40% and 75%, respectively) (p=0.002) and GAQ-2 (20%, 45%, and 75%, respectively) (p=0.002) was significant higher in the third group. There was no difference in the incidence of side effects between the groups (p= 0.392). CONCLUSIONS: Treatment of ED with oral tadalafil in patients with DM-related microvascular complications is ineffective when given daily or before intercourse. In these patients, giving the combination in the first step can provide higher efficacy and patient satisfaction with the same safety. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e589 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Goksel Bayar More articles by this author Caglar Yildirim More articles by this author Expand All Advertisement PDF DownloadLoading ...